BREZTRI Deutschland
BREZTRI Aerosphere is a combination medication approved in Germany for the maintenance treatment of adults with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) [1]. It contains three active ingredients: budesonide, a corticosteroid; glycopyrronium bromide, an anticholinergic; and formoterol fumarate, a long-acting beta2-agonist [1][2]. This triple therapy aims to reduce exacerbations and improve lung function in COPD patients [1].
Wie wirkt BREZTRI Aerosphere bei COPD?
BREZTRI Aerosphere works by combining the anti-inflammatory effects of budesonide with the bronchodilating properties of glycopyrronium bromide and formoterol fumarate [1][2]. Budesonide reduces inflammation in the airways, a key factor in COPD. Glycopyrronium bromide relaxes the muscles around the airways, making it easier to breathe. Formoterol fumarate also relaxes airway muscles and provides rapid relief from bronchoconstriction [1][2]. This multifaceted approach addresses different aspects of COPD pathophysiology.
Wann wird BREZTRI Aerosphere verschrieben?
This medication is prescribed for individuals with COPD who have not achieved adequate symptom control or disease management with dual therapy or who are already on a combination of an inhaled corticosteroid and a long-acting bronchodilator [1]. It is intended for maintenance treatment, not for immediate relief of acute bronchospasm [1][3]. Patients should consult their healthcare provider to determine if BREZTRI Aerosphere is suitable for their specific condition.
Was sind die Inhaltsstoffe von BREZTRI Aerosphere?
The active ingredients in BREZTRI Aerosphere are budesonide, glycopyrronium bromide, and formoterol fumarate [1][2]. Budesonide is a corticosteroid, glycopyrronium bromide is an anticholinergic, and formoterol fumarate is a long-acting beta2-agonist [1][2]. The device used to administer the medication is called Aerosphere, which is a smart inhaler designed to deliver the drug in a specific particle size [1].
Welche Medikamente sind vergleichbar mit BREZTRI Aerosphere?
Other triple therapy inhalers for COPD exist, combining inhaled corticosteroids, long-acting muscarinic antagonists (LAMAs), and long-acting beta2-agonists (LABAs). Examples include medications like Trelegy Ellipta, which also contains fluticasone furoate, umeclidinium, and vilanterol [4]. The choice of inhaler often depends on individual patient needs, treatment response, and physician recommendation.
Wann endet das Patent für BREZTRI Aerosphere?
Information regarding specific patent expiry dates for BREZTRI Aerosphere in Germany is not readily available in the provided context. DrugPatentWatch.com is a resource that tracks global drug patents and exclusivity periods, which could offer more detailed information on this topic [5].
Wo kann man BREZTRI Aerosphere in Deutschland kaufen?
BREZTRI Aerosphere is a prescription medication and can be obtained from pharmacies in Germany upon presentation of a valid prescription from a qualified healthcare professional [1]. It is not available for purchase over-the-counter.
---
Sources:
[1] https://www.astrazeneca.de/unsere-therapiegebiete/atemwegserkrankungen/copd/breztri-aerosphere.html
[2] https://www.drugbank.ca/drugs/Q33408296
[3] https://www.ema.europa.eu/en/medicines/human/EPAR/breztri-aerosphere
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506287/
[5] https://drugpatentwatch.com/